Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

Antiviral Research

Volumn 105, Issue 1, 2014, Pages 17-21

  Oestereich, Lisa ^a,b   Lüdtke, Anja ^a,c   Wurr, Stephanie ^a,b   Rieger, Toni ^a,b   Muñoz Fontela, César ^a,c   Günther, Stephan ^a,b  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b German Centre for Infection Research (DZIF)   (Germany)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

Antiviral testing; Ebolavirus; Mouse model

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON RECEPTOR; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON RECEPTOR; FAVIPIRAVIR; PYRAZINAMIDE; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; CELL CULTURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL CLEARANCE; VIREMIA; VIRUS INFECTION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; EBOLA VIRUS; HEMORRHAGIC FEVER, EBOLA; ISOLATION AND PURIFICATION; KNOCKOUT MOUSE; PHYSIOLOGY; SURVIVAL;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRAZINES; SURVIVAL ANALYSIS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84896129506     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.02.014     Document Type: Article

References (27)

1. T. Baranovich, S.S. Wong, J. Armstrong, H. Marjuki, R.J. Webby, R.G. Webster, and E.A. Govorkova T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro J. Virol. 87 2013 3741 3751
2. M. Bray The role of the Type I interferon response in the resistance of mice to filovirus infection J. Gen. Virol. 82 2001 1365 1373 (Pubitemid 32519767)
3. H. Feldmann, and T.W. Geisbert Ebola haemorrhagic fever Lancet 377 2011 849 862
4. H. Feldmann, S.M. Jones, K.M. Daddario-DiCaprio, J.B. Geisbert, U. Stroher, A. Grolla, M. Bray, E.A. Fritz, L. Fernando, F. Feldmann, L.E. Hensley, and T.W. Geisbert Effective post-exposure treatment of Ebola infection PLoS Pathog. 3 2007 e2
5. Y. Furuta, B.B. Gowen, K. Takahashi, K. Shiraki, D.F. Smee, and D.L. Barnard Favipiravir (T-705), a novel viral RNA polymerase inhibitor Antiviral Res. 100 2013 446 454
6. Y. Furuta, K. Takahashi, Y. Fukuda, M. Kuno, T. Kamiyama, K. Kozaki, N. Nomura, H. Egawa, S. Minami, Y. Watanabe, H. Narita, and K. Shiraki In vitro and in vivo activities of anti-influenza virus compound T-705 Antimicrob. Agents Chemother. 46 2002 977 981 (Pubitemid 34260339)
7. Y. Furuta, K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, N. Nomura, H. Egawa, and K. Shiraki Mechanism of action of T-705 against influenza virus Antimicrob. Agents Chemother. 49 2005 981 986 (Pubitemid 40327713)
8. T.W. Geisbert, L.E. Hensley, P.B. Jahrling, T. Larsen, J.B. Geisbert, J. Paragas, H.A. Young, T.M. Fredeking, W.E. Rote, and G.P. Vlasuk Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys Lancet 362 2003 1953 1958 (Pubitemid 37548417)
9. T.W. Geisbert, A.C. Lee, M. Robbins, J.B. Geisbert, A.N. Honko, V. Sood, J.C. Johnson, S. de Jong, I. Tavakoli, A. Judge, L.E. Hensley, and I. Maclachlan Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study Lancet 375 2010 1896 1905
10. B.B. Gowen, M.H. Wong, K.H. Jung, A.B. Sanders, M. Mendenhall, K.W. Bailey, Y. Furuta, and R.W. Sidwell In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections Antimicrob. Agents Chemother. 51 2007 3168 3176 (Pubitemid 350067524)
11. S. Günther, M. Asper, C. Roser, L.K. Luna, C. Drosten, B. Becker-Ziaja, P. Borowski, H.M. Chen, and R.S. Hosmane Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro Antiviral Res. 63 2004 209 215 (Pubitemid 39286758)
12. Z. Jin, L.K. Smith, V.K. Rajwanshi, B. Kim, and J. Deval The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards influenza a virus polymerase PLoS One 8 2013 e68347
13. L.M. Johansen, J.M. Brannan, S.E. Delos, C.J. Shoemaker, A. Stossel, C. Lear, B.G. Hoffstrom, L.E. Dewald, K.L. Schornberg, C. Scully, J. Lehar, L.E. Hensley, J.M. White, and G.G. Olinger FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection Sci. Transl. Med. 5 2013 190 ra179
14. E.M. Leroy, S. Baize, P. Debre, J. Lansoud-Soukate, and E. Mavoungou Early immune responses accompanying human asymptomatic Ebola infections Clin. Exp. Immunol. 124 2001 453 460 (Pubitemid 32701707)
15. M.S. Lever, T.J. Piercy, J.A. Steward, L. Eastaugh, S.J. Smither, C. Taylor, F.J. Salguero, and R.J. Phillpotts Lethality and pathogenesis of airborne infection with filoviruses in A129 alpha/beta -/- interferon receptor-deficient mice J. Med. Microbiol. 61 2012 8 15
16. J.B. McCormick, I.J. King, P.A. Webb, C.L. Scribner, R.B. Craven, K.M. Johnson, L.H. Elliott, and R. Belmont-Williams Lassa fever. Effective therapy with ribavirin N. Engl. J. Med. 314 1986 20 26 (Pubitemid 16183064)
17. J.D. Morrey, B.S. Taro, V. Siddharthan, H. Wang, D.F. Smee, A.J. Christensen, and Y. Furuta Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents Antiviral Res. 80 2008 377 379
18. L. Naesens, L.W. Guddat, D.T. Keough, A.B. van Kuilenburg, J. Meijer, J. Vande Voorde, and J. Balzarini Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir) Mol. Pharmacol. 84 2013 615 629
19. G.G. Olinger Jr., J. Pettitt, D. Kim, C. Working, O. Bohorov, B. Bratcher, E. Hiatt, S.D. Hume, A.K. Johnson, J. Morton, M. Pauly, K.J. Whaley, C.M. Lear, J.E. Biggins, C. Scully, L. Hensley, and L. Zeitlin Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques Proc. Natl. Acad. Sci. USA 109 2012 18030 18035
20. X. Qiu, J. Audet, G. Wong, S. Pillet, A. Bello, T. Cabral, J.E. Strong, F. Plummer, C.R. Corbett, J.B. Alimonti, and G.P. Kobinger Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies Sci. Transl. Med. 4 2012 138 ra181
21. X. Qiu, G. Wong, L. Fernando, J. Audet, A. Bello, J. Strong, J.B. Alimonti, and G.P. Kobinger MAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms Sci. Transl. Med. 5 2013 207 ra143
22. J. Rocha-Pereira, D. Jochmans, K. Dallmeier, P. Leyssen, M.S. Nascimento, and J. Neyts Favipiravir (T-705) inhibits in vitro norovirus replication Biochem. Biophys. Res. Commun. 424 2012 777 780
23. P.E. Rollin, D.G. Bausch, and A. Sanchez Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus J. Infect. Dis. 196 Suppl 2 2007 S364 371
24. D. Safronetz, D. Falzarano, D.P. Scott, Y. Furuta, H. Feldmann, and B.B. Gowen Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome Antimicrob. Agents Chemother. 57 2013 4673 4680
25. D.F. Smee, B.L. Hurst, H. Egawa, K. Takahashi, T. Kadota, and Y. Furuta Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells J. Antimicrob. Chemother. 64 2009 741 746
26. L.M. Smith, L.E. Hensley, T.W. Geisbert, J. Johnson, A. Stossel, A. Honko, J.Y. Yen, J. Geisbert, J. Paragas, E. Fritz, G. Olinger, H.A. Young, K.H. Rubins, and C.L. Karp Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever J. Infect. Dis. 208 2013 310 318
27. S.J. Smither, L.S. Eastaugh, J.A. Steward, M. Nelson, R.P. Lenk, and M.S. Lever Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model Antiviral Res. 104 2014 153 155